FDA OKs Isentress Indication for HIV-1 Exposed Newborns
November 30th 2017The FDA has extended the approval of raltegravir (Isentress, Merck), an integrase inhibitor for use in combination with other antiretroviral agents, for the treatment of HIV-1 in newborn infants weighing at least 2 kg.
Read More